Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06112990 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression

Study acronym: CREATINE-52
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Secondary endpoints expanded, about 249 words Study description expanded, about 3 wordsv6 Show 1 more changeShow less
    • Study description expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study description revisedv5 See this version in full on ClinicalTrials.gov ↗
  3. Primary endpoint revised Primary completion date: Nov 1, 2028 to Nov 30, 2028 · Completion date: Nov 1, 2029 to Nov 30, 2028 · Start date: Oct 31, 2023 to Nov 9, 2023 · 3 morev4 Show 6 more changesShow less
    • Primary completion date: Nov 1, 2028 to Nov 30, 2028
    • Completion date: Nov 1, 2029 to Nov 30, 2028
    • Start date: Oct 31, 2023 to Nov 9, 2023
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints shortened, about 267 words
    • Collaborator revised

    See this version in full on ClinicalTrials.gov ↗

  4. Eligibility criteria shortened, about 40 wordsv3 See this version in full on ClinicalTrials.gov ↗
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 15, 2023 to Oct 31, 2023 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Nov 15, 2023 to Oct 31, 2023
    • Site details revised
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression. The main question it aims to answer is if this treatment will help maintain muscle mass to help in reducing fatigue and improving physical function, independence, and quality of life. Participants will be asked to participate in a 52-week exercise intervention consisting of a twice weekly telehealth resistance training program.
Trial Details
NCT Number NCT06112990
Lead Sponsor University of Utah
Collaborators: National Cancer Institute (NCI)
Conditions Metastatic Prostate Cancer
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov